Skip to content

Evaluation of adding Vitix gel on vitiligo lesions treating with NB-UVB phototherapy in patients referring to dermatology clinic of Quaem hospital

Evaluation of adding Vitix gel on vitiligo lesions treating with NB-UVB phototherapy in patients referring to dermatology clinic of Quaem hospital

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015011216955N2
Enrollment
30
Registered
2015-12-13
Start date
2014-08-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: NB-UVB phototherapy was administered on lesions of both sides of the body, three times per week on non consecutive days for 40 sessions or 4 months. Intervention 2
Treatment - Drugs
Intervention group: NB-UVB phototherapy was administered on lesions of both sides of the body, three times per week on non consecutive days for 40 sessions or 4 months.
Control group: Each patient acted as his/her own control as while NB-UVB phototherapy was administered on lesions of both sides of the body whereas Vitix® gel (ACM, France) was applied on just one sid

Sponsors

Vice Chancellor for Research of Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Bilateral symmetrical lesions distributed on face or limbs that involving more than 10% of body surface; age>12 years; who had signed a written informed consent. exclusion criteria: pregnancy; breast feeding; any history of previous hypersensitivity to Vitix gel; having skin malignancy; history of immunosuppression or taking immunosuppressive drugs; any contraindications for phototherapy; previous treatment with phototherapy from 3 months ago; history of photosensitivity; history of psychologic disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Lesion improvement based on amount of repigmentation. Timepoint: Monthly for 4 months. Method of measurement: Calculation the repigmentation score according to a certain classification.

Secondary

MeasureTime frame
Side effects. Timepoint: Monthly. Method of measurement: Based on history, physical examination and observation of the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Pouran Layegh

Mashhad University of Medical Sciences

layeghpo@mums.ac.ir+98 51 3801 2851

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026